T-cell research reveals paths to better vaccines for COVID-19 and beyond

Two individuals infected with the same COVID-19 strain can experience vastly different outcomes, ranging from no symptoms to severe illness. Researchers are investigating the role of T cells, a type of white blood cell that mounts an immune response, particularly CD8+ T cells that can fight off COVID-19 infections. However, most studies have not accounted for individual variations in the immune system.

Moriya Tsuji, a professor at Texas A&M University School of Engineering Medicine, emphasized the importance of considering human leukocyte antigens (HLAs), which help determine how the immune system recognizes viral pieces and activates T cells. HLA types vary among individuals, and understanding these differences can guide treatment and vaccine development.

Tsuji and his team analyzed blood samples from 42 HLA-A2-positive patients, all of whom carried the same HLA type. They identified that patients with mild COVID-19 had more CD8+ T cells, which mounted a strong, multifunctional response lasting up to four months. In contrast, severe disease patients exhibited dysfunctional T-cell types, suggesting a weakened immune response.

Tsuji highlighted that many virus targets recognized by CD8+ T cells remain unchanged across variants, as they are located within the virus rather than on its surface. By comparing CD8+ T cell responses from mild versus severe patients in a controlled manner, the study provides valuable insights into potential T-cell-based vaccines.

Further research will aim to establish a direct causal relationship between these T-cell responses and protection, paving the way for next-generation COVID-19 vaccines that can mitigate the virus's ability to mutate.